Pancreas Cancer Clinical Trials in Boston, Massachusetts

7 studies are recruiting for pancreas cancer in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

   Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Massachusetts General Hospital/Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   16 in total

   Run by

   A2 Biotherapeutics Inc.

   See if you can join NCT04981119 on ClinicalTrials.gov

2. Pancreatic Cancer Early Detection Consortium

   The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   60 in total

   Run by

   Arbor Research Collaborative for Health

   See if you can join NCT04970056 on ClinicalTrials.gov

3. Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury

   The goal of this study is to investigate the efficacy of [68Ga]CBP8 to detect collagen deposition in radiation induced tissue injury.

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Run by

   Massachusetts General Hospital

   See if you can join NCT04485286 on ClinicalTrials.gov

4. SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

   The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic breast cancer. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, vitamin B12b, and vitam…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   General Oncology, Inc.

   See if you can join NCT04150042 on ClinicalTrials.gov

5. Stereotactic Magnetic Resonance Guided Radiation Therapy

   This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Ph…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Brigham & Women's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT04115254 on ClinicalTrials.gov

6. The Cancer of the Pancreas Screening-5 CAPS5)Study

   Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Dana Farber Cancer Center, Harvard University, Boston, Massachusetts

   Locations

   9 in total

   Run by

   Johns Hopkins University

   See if you can join NCT02000089 on ClinicalTrials.gov

7. Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

   The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana Farber/Partners Cancer Care Inc, Boston, Massachusetts

   Locations

   20 in total

   Run by

   Bicara Therapeutics

   See if you can join NCT04429542 on ClinicalTrials.gov